Patriot Financial Group Insurance Agency LLC Has $606,000 Stock Holdings in GSK plc (NYSE:GSK)

Patriot Financial Group Insurance Agency LLC boosted its position in shares of GSK plc (NYSE:GSK) by 9.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,910 shares of the pharmaceutical company’s stock after purchasing an additional 1,502 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in GSK were worth $606,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Eastern Bank bought a new stake in shares of GSK in the 3rd quarter valued at $26,000. ST Germain D J Co. Inc. increased its holdings in shares of GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares in the last quarter. Sunbelt Securities Inc. raised its position in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners lifted its holdings in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC acquired a new position in shares of GSK in the 3rd quarter valued at approximately $42,000. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

NYSE:GSK opened at $35.12 on Wednesday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a market cap of $72.78 billion, a P/E ratio of 22.80, a P/E/G ratio of 1.31 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The stock’s 50-day simple moving average is $33.94 and its 200 day simple moving average is $37.78.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.